277 related articles for article (PubMed ID: 8789141)
1. Prediction of human immunodeficiency virus protease cleavage sites in proteins.
Chou KC
Anal Biochem; 1996 Jan; 233(1):1-14. PubMed ID: 8789141
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 protease cleavage site prediction based on amino acid property.
Niu B; Lu L; Liu L; Gu TH; Feng KY; Lu WC; Cai YD
J Comput Chem; 2009 Jan; 30(1):33-9. PubMed ID: 18496789
[TBL] [Abstract][Full Text] [Related]
3. Support Vector Machines for predicting HIV protease cleavage sites in protein.
Cai YD; Liu XJ; Xu XB; Chou KC
J Comput Chem; 2002 Jan; 23(2):267-74. PubMed ID: 11924738
[TBL] [Abstract][Full Text] [Related]
4. A vector projection approach to predicting HIV protease cleavage sites in proteins.
Chou KC; Zhang CT; Kézdy FJ
Proteins; 1993 Jun; 16(2):195-204. PubMed ID: 8332607
[TBL] [Abstract][Full Text] [Related]
5. Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method.
Chou KC; Tomasselli AG; Reardon IM; Heinrikson RL
Proteins; 1996 Jan; 24(1):51-72. PubMed ID: 8628733
[TBL] [Abstract][Full Text] [Related]
6. Variable context Markov chains for HIV protease cleavage site prediction.
Oğul H
Biosystems; 2009 Jun; 96(3):246-50. PubMed ID: 19758550
[TBL] [Abstract][Full Text] [Related]
7. A formulation for correlating properties of peptides and its application to predicting human immunodeficiency virus protease-cleavable sites in proteins.
Chou JJ
Biopolymers; 1993 Sep; 33(9):1405-14. PubMed ID: 8400033
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?
Towler EM; Gulnik SV; Bhat TN; Xie D; Gustschina E; Sumpter TR; Robertson N; Jones C; Sauter M; Mueller-Lantzsch N; Debouck C; Erickson JW
Biochemistry; 1998 Dec; 37(49):17137-44. PubMed ID: 9860826
[TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity.
Hoog SS; Towler EM; Zhao B; Doyle ML; Debouck C; Abdel-Meguid SS
Biochemistry; 1996 Aug; 35(32):10279-86. PubMed ID: 8756683
[TBL] [Abstract][Full Text] [Related]
10. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
[TBL] [Abstract][Full Text] [Related]
11. A side chain at position 48 of the human immunodeficiency virus type-1 protease flap provides an additional specificity determinant.
Moody MD; Pettit SC; Shao W; Everitt L; Loeb DD; Hutchison CA; Swanstrom R
Virology; 1995 Mar; 207(2):475-85. PubMed ID: 7886951
[TBL] [Abstract][Full Text] [Related]
12. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease.
Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS
Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985
[TBL] [Abstract][Full Text] [Related]
13. HIVcleave: a web-server for predicting human immunodeficiency virus protease cleavage sites in proteins.
Shen HB; Chou KC
Anal Biochem; 2008 Apr; 375(2):388-90. PubMed ID: 18249180
[TBL] [Abstract][Full Text] [Related]
14. Mining HIV protease cleavage data using genetic programming with a sum-product function.
Yang ZR; Dalby AR; Qiu J
Bioinformatics; 2004 Dec; 20(18):3398-405. PubMed ID: 15256407
[TBL] [Abstract][Full Text] [Related]
15. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.
Wang YX; Freedberg DI; Yamazaki T; Wingfield PT; Stahl SJ; Kaufman JD; Kiso Y; Torchia DA
Biochemistry; 1996 Aug; 35(31):9945-50. PubMed ID: 8756455
[TBL] [Abstract][Full Text] [Related]
16. Accurate prediction of HIV-1 drug response from the reverse transcriptase and protease amino acid sequences using sparse models created by convex optimization.
Rabinowitz M; Myers L; Banjevic M; Chan A; Sweetkind-Singer J; Haberer J; McCann K; Wolkowicz R
Bioinformatics; 2006 Mar; 22(5):541-9. PubMed ID: 16368772
[TBL] [Abstract][Full Text] [Related]
17. Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors.
Savarino A; Cauda R; Cassone A
J Infect Dis; 2005 Apr; 191(8):1381-2; author reply 1382-3. PubMed ID: 15776390
[No Abstract] [Full Text] [Related]
18. Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures.
Tong L; Pav S; Pargellis C; Dô F; Lamarre D; Anderson PC
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8387-91. PubMed ID: 8378311
[TBL] [Abstract][Full Text] [Related]
19. Studies on the specificity of HIV protease: an application of Markov chain theory.
Chou KC; Zhang CT
J Protein Chem; 1993 Dec; 12(6):709-24. PubMed ID: 8136021
[TBL] [Abstract][Full Text] [Related]
20. New database.
Vondrasek J; Wlodawer A
Science; 1996 Apr; 272(5260):337-8. PubMed ID: 8602518
[No Abstract] [Full Text] [Related]
[Next] [New Search]
